Herceptin News and Research

RSS
Roche’s new breast cancer drug Pertuzumab up for FDA review

Roche’s new breast cancer drug Pertuzumab up for FDA review

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

Pertuzumab plus trastuzumab and docetaxel has advantages over current clinical gold-standard treatment

C&EN explains logic behind odd-sounding generic names

C&EN explains logic behind odd-sounding generic names

Combination of lapatinib and trastuzumab more effective in treating HER2-positive breast cancer

Combination of lapatinib and trastuzumab more effective in treating HER2-positive breast cancer

Researchers create vaccine that reduces tumors in mice

Researchers create vaccine that reduces tumors in mice

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

Obese women with early-stage HER2-positive breast cancer may have poorer outcomes

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

HER2 proteins do not predict breast cancer patient's outcome after Herceptin treatment

Breast cancer hope with new drug and new combination regimens

Breast cancer hope with new drug and new combination regimens

Initial results from whole-genome sequencing trial for triple negative breast cancer

Initial results from whole-genome sequencing trial for triple negative breast cancer

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Positive results from Synta's Ganetespib Phase 2 trial on HER2-positive and triple negative mBC

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

First results from whole-genome sequencing clinical trial on triple negative breast cancer

First results from whole-genome sequencing clinical trial on triple negative breast cancer

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Lapatinib could extend survival in women with Her2-positive breast cancer

Lapatinib could extend survival in women with Her2-positive breast cancer

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Positive results from Roche's Phase 3 HannaH trial for HER2-positive early breast cancer

Strain echocardiography can help physicians detect early signs of cardiac toxicity in cancer patients

Strain echocardiography can help physicians detect early signs of cardiac toxicity in cancer patients

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

Herceptin chemo combination could mean longer survival and lower side effects in breast cancer patients: Study

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Breast cancer drug combination could stop cancer “in its tracks”

Breast cancer drug combination could stop cancer “in its tracks”

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions

Survey: 35% of people in the UK fear cancer more than other life-threatening conditions